Structure Therapeutics (NASDAQ:GPCR) Trading Up 6% – Time to Buy?

Structure Therapeutics Inc. (NASDAQ:GPCR) shares rose 6% during trading on Wednesday . The stock traded as high as $21.99 and last traded at $22.39. Approximately 59,438 shares changed hands during mid-day trading, a decline of 93% from the average daily volume of 838,890 shares. The stock had previously closed at $21.11.

Analyst Upgrades and Downgrades

GPCR has been the subject of a number of recent analyst reports. William Blair started coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They issued an “outperform” rating for the company. Stifel Nicolaus initiated coverage on Structure Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective for the company. JMP Securities reaffirmed a “market outperform” rating and issued a $91.00 target price on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Finally, HC Wainwright reissued a “buy” rating and set a $80.00 price target on shares of Structure Therapeutics in a research report on Thursday, December 19th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Stock Performance

The firm has a fifty day moving average of $25.08 and a 200 day moving average of $32.09. The firm has a market capitalization of $1.31 billion, a PE ratio of -31.16 and a beta of -2.37.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. Research analysts forecast that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd increased its holdings in Structure Therapeutics by 115.0% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock worth $28,000 after purchasing an additional 553 shares during the last quarter. GAMMA Investing LLC raised its holdings in Structure Therapeutics by 4,155.6% in the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after acquiring an additional 1,122 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in Structure Therapeutics during the 4th quarter valued at $34,000. FNY Investment Advisers LLC acquired a new position in Structure Therapeutics during the 4th quarter worth $40,000. Finally, Assetmark Inc. lifted its position in shares of Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after purchasing an additional 719 shares during the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.